Dynavax Technologies Corporation

NasdaqGS:DVAX Stock Report

Market Cap: US$1.3b

Dynavax Technologies Management

Management criteria checks 3/4

Dynavax Technologies' CEO is Ryan Spencer, appointed in Dec 2019, has a tenure of 5.33 years. total yearly compensation is $8.21M, comprised of 10.2% salary and 89.8% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $2.69M. The average tenure of the management team and the board of directors is 4.3 years and 6.8 years respectively.

Key information

Ryan Spencer

Chief executive officer

US$8.2m

Total compensation

CEO salary percentage10.2%
CEO tenure5.3yrs
CEO ownership0.2%
Management average tenure4.3yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

We Think Dynavax Technologies' (NASDAQ:DVAX) Profit Is Only A Baseline For What They Can Achieve

Mar 04
We Think Dynavax Technologies' (NASDAQ:DVAX) Profit Is Only A Baseline For What They Can Achieve

Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share

Mar 03

Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018

Feb 05

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Jan 24
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Dynavax Technologies: What The Stock Buyback Means, What It Doesn't

Nov 13

Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Nov 12
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Oct 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
author-image

HEPLISAV-B And New Vaccine Trials Set To Skyrocket Revenue And Market Share

Sep 14 Strong HEPLISAV-B sales and market optimism indicate potential for revenue growth and market share expansion in the adult hepatitis B vaccine sector.

Dynavax Technologies: Slow And Steady Wins The Race

Sep 05

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick

Aug 23

Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Aug 14
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02
Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03
We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16
Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

CEO Compensation Analysis

How has Ryan Spencer's remuneration changed compared to Dynavax Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$8mUS$835k

US$27m

Sep 30 2024n/an/a

US$20m

Jun 30 2024n/an/a

US$17m

Mar 31 2024n/an/a

US$9m

Dec 31 2023US$6mUS$760k

-US$6m

Sep 30 2023n/an/a

US$61m

Jun 30 2023n/an/a

US$111m

Mar 31 2023n/an/a

US$236m

Dec 31 2022US$6mUS$695k

US$293m

Sep 30 2022n/an/a

US$320m

Jun 30 2022n/an/a

US$228m

Mar 31 2022n/an/a

US$104m

Dec 31 2021US$5mUS$600k

US$72m

Sep 30 2021n/an/a

-US$39m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$62m

Dec 31 2020US$2mUS$515k

-US$75m

Sep 30 2020n/an/a

-US$97m

Jun 30 2020n/an/a

-US$138m

Mar 31 2020n/an/a

-US$129m

Dec 31 2019US$3mUS$391k

-US$156m

Compensation vs Market: Ryan's total compensation ($USD8.21M) is above average for companies of similar size in the US market ($USD5.94M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.

CEO

Ryan Spencer (46 yo)

5.3yrs

Tenure

US$8,210,775

Compensation

Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as the Chief Executive Officer and Director of Dynavax Technologies Corporation since December 16...

Leadership Team

NamePositionTenureCompensationOwnership
Ryan Spencer
CEO & Director5.3yrsUS$8.21m0.21%
$ 2.7m
David Novack
President & COO12.1yrsUS$3.73m0.0065%
$ 83.3k
Kelly MacDonald
Senior VP4.1yrsUS$2.63m0.024%
$ 301.4k
John Slebir
Senior VP & General Counsel3.8yrsUS$2.85mno data
Robert Janssen
Chief Medical Officer and Senior VP of Clinical Development11.8yrsUS$2.28m0.062%
$ 798.8k
Jeff Coon
Senior VP & Chief Human Resources Officer6.3yrsno datano data
Paul Cox
VP of Investor Relations & Corporate Communications2.3yrsno datano data
Donn Casale
Senior VP & Chief Commercial Officerno datano datano data
Dong Yu
Senior Vice President of Research4.2yrsno datano data
Eric Frings
VP, Site Head & MD for Dynavax GmbH4.3yrsno datano data
Todd Lopeman
Senior Vice President of Technical Operations4.3yrsno datano data
Riccardo Manetti
Senior Vice President of Business Development2.3yrsno datano data

4.3yrs

Average Tenure

59.5yo

Average Age

Experienced Management: DVAX's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ryan Spencer
CEO & Director5.3yrsUS$8.21m0.21%
$ 2.7m
Peggy Phillips
Independent Director18.7yrsUS$305.64k0.022%
$ 285.9k
Daniel Kisner
Independent Director14.8yrsUS$297.64k0.0012%
$ 15.5k
Francis Cano
Independent Director15.4yrsUS$285.64k0.017%
$ 214.8k
Robert Coffman
Member of Scientific Advisory Board2.3yrsUS$1.83mno data
Andrew Pardoll
Member of Scientific Advisory Board6.8yrsno datano data
Julie Eastland
Independent Director4.8yrsUS$300.64k0%
$ 0
Stanley Plotkin
Member of Scientific Advisory Board6.8yrsUS$20.00kno data
Scott Myers
Independent Chairman of the Board3.5yrsUS$330.64k0%
$ 0
Miriam Merad
Member of Scientific Advisory Board6.8yrsno datano data
Laura Q. Chow
Member of Scientific Advisory Board6.8yrsno datano data
E. Wherry
Member of Scientific Advisory Board6.8yrsno datano data

6.8yrs

Average Tenure

73.5yo

Average Age

Experienced Board: DVAX's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/21 15:21
End of Day Share Price 2025/04/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dynavax Technologies Corporation is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elemer PirosCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC
Douglas BuchananCitizens JMP Securities, LLC